The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NVO 0.69%) did during the GLP-1 ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug met the main goal of a late-stage study in children and adolescents aged ...

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

A late-stage trial showed that oral semaglutide significantly reduced blood sugar in 10- to 17-year-olds.

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors ...

Novo Nordisk said it will approach regulators with the data on the SCD therapy in H2 2026.

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has lost around 60% of its value. Things have been going from bad to worse for the ...